Omeros Corporation (NASDAQ:OMER – Get Free Report) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $18.00.
OMER has been the topic of a number of analyst reports. HC Wainwright initiated coverage on shares of Omeros in a research report on Tuesday, June 10th. They issued a “buy” rating and a $9.00 price objective on the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, May 16th.
Check Out Our Latest Research Report on OMER
Hedge Funds Weigh In On Omeros
Omeros Stock Down 0.3%
Omeros stock opened at $3.21 on Monday. The firm has a fifty day simple moving average of $4.80 and a two-hundred day simple moving average of $7.39. Omeros has a twelve month low of $2.97 and a twelve month high of $13.60. The company has a market capitalization of $188.07 million, a PE ratio of -1.21 and a beta of 2.21.
Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). As a group, equities analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
- Five stocks we like better than Omeros
- Bank Stocks – Best Bank Stocks to Invest In
- The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
- Investing in Travel Stocks Benefits
- More Than a Monetary Metal: Silver’s Case for Outperformance
- 3 Small Caps With Big Return Potential
- Retail Sales Signal Upside for These 3 Consumer Stocks
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.